Boucheix OB et al: Selepressin, a new V1A receptor agonist: Hemodynamic comparison to vasopressin in dogs. Shock 2013;39:533.
Fujiwara Y et al: The roles of V1a vasopressin receptors in blood pressure homeostasis: A review of studies on V1a receptor knockout mice. Clin Exp Nephrol 2012;16:30.
Koshimizu TA et al: Vasopressin V1a and V1b receptors: From molecules to physiological systems. Physiol Rev 2012;92:1813.
Palmer BF: Vasopressin receptor antagonists. Curr Hypertens Rep 2015;17:510.
Anker SD et al: Ularitide for the treatment of acute decompensated heart failure: From preclinical to clinical studies. Eur Heart J 2015;36:715.
Boerrigter G, Burnett JC Jr: Natriuretic peptides renal protective after all? J Am Coll Cardiol 2011;58:904.
Federico C: Natriuretic peptide system and cardiovascular disease. Heart Views 2010;11:1.
Jhund PS, McMurray JJ: The neprilysin pathway in heart failure: A review and guide on the use of sacubitril/valsartan. Heart 2016;102:1342.
Prenner SB et al: Role of angiotensin receptor-neprilysin inhibition in heart failure. Curr Atheroscler Rep 2016;18:48.
Rubattu S et al: Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: Implications for novel therapeutic strategies. J Hypertens 2013;31:1061.
Ruilope LM et al: Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255.
Saito Y: Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 2010;56:262.
Vilela-Martin JF: Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: The evidence to date. Drug Des Devel Ther 2016;10:1627.
Vogel MW, Chen HH: Novel natriuretic peptides: New compounds and new approaches. Curr Heart Fail Rep 2011;8:22.
Volpe M et al: The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment. Clin Sci (Lond) 2016;130:57.
Davenport AP et al: Endothelin. Pharmacol Rev 2016;68:357.
Kawanabe Y, Nauli SM: Endothelin. Cell Mol Life Sci 2011;68:195.
Pulido T et al: Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809.
Sidharta PN, van Giersbergen PL, Dingemanse J: Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol 2013;53:1131.